on NEOVACS (EPA:ALNEV)
Termination of the financing contract granted to Pharnext
Neovacs, a preclinical-stage biopharmaceutical company, announced the early termination of its financing agreement with Pharnext. This contract, concluded in September 2022 and managed by a trustee since October 2022, was revoked due to defects reported by Pharnext on July 3, 2024.
As a result, the trustee responsible for managing the agreement asked Pharnext to repay the remaining €22 million. If this request is not honored, the trustee reserves the right to enforce the security interests granted, including the intellectual property, bank accounts and insurance claims of Pharnext.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all NEOVACS news